Beneficial pharmacokinetic drug interactions: A tool to improve the bioavailability of poorly permeable drugs

Pharmaceutics

Volumn 10, Issue 3, 2018, Pages

  Gerber, Werner ^a   Steyn, Johan D ^a   Kotzé, Awie F ^a   Hamman, Josias H ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Bioavailability; Efflux inhibition; Enzyme inhibition; Pharmacokinetic interactions; Tight junction modulation

Indexed keywords

ABC TRANSPORTER SUBFAMILY B; CAROTENOID; CHLORAMBUCIL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EMODIN; GLYCYRRHIZA GLABRA ROOT; IVERMECTIN; LOPINAVIR; NIFEDIPINE; ORGANIC CATION TRANSPORTER 2; PIPERINE; RESVERATROL; SAQUINAVIR; TELAPREVIR;

ACTIVE TRANSPORT; ALOE; ANDROGRAPHIS PANICULATA; BLACK PEPPER; COFFEE; DIETARY SUPPLEMENT; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HERB DRUG INTERACTION; HUMAN; NONHUMAN; ORANGE JUICE; PLANT LEAF; REVIEW; SALVIA MILTIORRHIZA;

EID: 85051280639     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics10030106     Document Type: Review

References (60)

1. Edwards, D.J. Beneficial pharmacokinetic drug interactions. Adv. Pharmacoepidemiol. Drug Saf. 2012, 1, 2.
2. Li, X.; Hu, J.; Wang, B.; Sheng, L.; Liu, Z.; Yang, S.; Li, Y. Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: Herb-drug interactions mediated via P-gp. Toxicol. Appl. Pharmacol. 2014, 275, 163–175.
3. Che, C.; Wang, Z.J.; Chow, M.S.S.; Lam, C.W.K. Herb-herb combination for therapeutic enhancement and advancement: Theory, practice and future perspectives. Molecules 2013, 18, 5125–5141.
4. Mouly, S.; Lloret-Linares, C.; Sellier, P.; Sene, D.; Bergmann, J. Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John’s Wort? Pharmacol. Res. 2017, 118, 82–92.
5. Jia, Y.; Liu, Z.; Wang, C.; Meng, Q.; Huo, X.; Liu, Q.; Sun, H.; Sun, P.; Yang, X.; Ma, X. et al. P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate. Toxicol. Appl. Pharmacol. 2016, 306, 27–35.
6. Renukuntla, J.; Vadlapudi, A.D.; Patel, A.; Boddu, A.H.S.; Mitra, A.K. Approaches for enhancing oral bioavailability of peptides and proteins. Int. J. Pharm. 2013, 447, 75–93.
7. He, L.; Vasiliou, K.; Nebert, D.W. Analysis and update of the human solute carrier (SLC) gene superfamily. Hum. Genom. 2009, 3, 195–206.
8. Hediger, M.A.; Romero, M.F.; Peng, J.B.; Rolfs, A.; Takanaga, H.; Bruford, E.A. The ABCs of solute carriers: Physiological, pathological and therapeutic implications of human membrane transport proteins. Eur. J. Physiol. 2004, 447, 465–468.
9. Sugano, K.; Kansy, M.; Artursson, P.; Avdeef, A.; Bendels, S.; Di, L.; Ecker, G.F.; Faller, B.; Fischer, H.; Gerebtzoff, G. et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat. Rev. Drug Discov. 2010, 9, 597–614.
10. Ballent, M.; Maté, L.; Virkel, G.; Sallovitz, J.; Viviani, P.; Lanusse, C.; Lifschitz, A. Intestinal drug transport: Ex vivo evaluation of the interactions between ABC transporters and anthelmintic molecules. J. Vet. Pharmacol. Ther. 2014, 37, 332–337.
11. Liu, T.; Peng, Y.; Li, X.; Liu, L.; Liu, F.; He, L. A novel delocalized lipophilic cation-chlorambucil conjugate inhibits P-glycoprotein in HepG2/ADM cells. Bioorg. Med. Chem. 2017, 25, 5461–5467.
12. Zhao, W.; Uehera, S.; Tanaka, K.; Tadokoro, S.; Kusamori, K.; Katsumi, H.; Sakane, T.; Yamamoto, A. Effects of polyoxyethylene alkyl ethers on the intestinal transport and absorption of rhodamine 123: A P-glycoprotein substrate by in vitro and in vivo studies. J. Pharm. Sci. 2016, 105, 1526–1534.
13. Kunze, A.; Huwyler, J.; Camenisch, G.; Gutmann, H. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem. Pharmacol. 2012, 84, 1096–1102.
14. Uwai, Y.; Ozeki, Y.; Isaka, T.; Honjo, H.; Iwamoto, K. Inhibitory effect of caffeic acid in human organic anion transporters hOAT1 and hOAT3: A novel candidate for food-drug interaction. Drug Metab. Pharmacokinet. 2011, 26, 486–493.
15. Wang, L.; Sweet, D.H. Interaction of natural dietary and herbal anionic compounds and flavonoids with human organic anion transporters 1 (SLC22A6), 3 (SLC22A8), and 4 (SLC22A11). Evid. Based Complement. Alternat. Med. 2013, 2013, 612527.
16. He, W.; Wu, J.; Ning, J.; Hou, J.; Xin, H.; He, Y.; Ge, G.; Xu, X. Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice. Toxicol. In Vitro 2015, 29, 1569–1576.
17. Gonzalez, F.J.; Coughtrie, M.; Tukey, R.H. Drug Metabolism. In Goodman & Gillman’s The Pharmacological Bases of Therapeutics, 12th ed.; Brunton, L.L., Chabner, B.A., Knollman, B.C., Eds.; McGraw Hill: New York, NY, USA, 2011; pp. 124–143. ISBN 978–0071624428.
18. Li, G.; Simmler, C.; Chen, L.; Nikolic, D.; Chen, S.; Pauli, G.F.; van Breemen, R.B. Cytochrome P450 inhibition by three licorice species and fourteen licorice constituents. Eur. J. Pharm. Sci. 2017, 109, 182–190.
19. Husni, Z.; Ismail, S.; Zulkiffli, M.H.; Afandi, A.; Haron, M. In vitro inhibitory effects of Andrographis paniculata, Gynura procumbens, Ficus deltoidea, and Curcuma xanthorrhiza extracts and constituents on human liver glucuronidation activity. Pharmacogn. Mag. 2017, 13, 236–243.
20. Zheng, Y.F.; Min, J.S.; Kim, D.; Park, J.B.; Choi, S.; Lee, E.S.; Na, K.; Bae, S.K. In vitro inhibition of human UDP-glucuronosyl-transferase (UGT) isoforms by astaxanthin, β-cryptoxanthin, canthaxanthin, lutein and zeaxanthin: Prediction of in vivo dietary supplement-drug interactions. Molecules 2016, 21.
21. Bock, K.W. Roles of human UDP-glucuronosyltransferases in clearance and homeostasis of endogenous substrates, and functional implications. Biochem. Pharmacol. 2015, 96, 77–82.
22. Liu, Y.; Coughtrie, M.W.H. Revisiting the latency of uridine diphosphate-glucuronosyltransferases (UGTs)—How does the endoplastic reticulum membrane influence their function? Pharmaceutics 2017, 9, 32.
23. Mohamed, M.F.; Frye, R.F. Inhibitory effects of commonly used herbal extracts on UDP-Glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities. Drug Metab. Dispos. 2011, 39, 1522–1528.
24. Fugh-Berman, A. Herb-drug interactions. Lancet 2000, 355, 134–138.
25. Hu, Z.; Yang, X.; Ho, P.C.L.; Chan, S.Y.; Heng, P.W.S.; Chan, E.; Duan, W.; Koh, H.L.; Zhou, S. Herb-drug interactions a literature review. Drugs 2005, 65, 1239–1282.
26. Merriam-Webster’s Medical Dictionary. Available online: https://www.merriam-webster.com/dictionary/food (accessed on 23 August 2017).
27. Baily, D.G.; Spence, J.D.; Munoz, C.; Arnold, M.O. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991, 337, 268–269.
28. Bhardwaj, K.R.; Glaeser, H.; Becquemont, L.; Klotz, U.; Gupta, S.K.; Fromm, M.F. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 2002, 302, 645–650.
29. Di, X.; Wang, X.; Di, X.; Liu, Y. Effect of piperine on the bioavailability and pharmacokinetics of emodin in rats. J. Pharm. Biomed. Anal. 2015, 115, 144–149.
30. Li, C.; Wang, Q.; Ren, T.; Zhang, Y.; Lam, C.W.K.; Chow, M.S.S.; Zuo, Z. Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. J. Pharm. Biomed. Anal. 2016, 128, 286–293.
31. Shao, B.; Cui, C.; Ji, H.; Tang, J.; Wang, Z.; Liu, H.; Qin, M.; Li, X.; Wu, L. Enhanced oral bioavailability of piperine by self-emulsifying drug delivery systems: In vitro, in vivo and in situ intestinal permeability studies. Drug Deliv. 2015, 22, 740–747.
32. Fleisher, B.; Unum, J.; Shao, J.; An, G. Ingredients in fruit juices interact with Dasatinib through inhibition of BCRP: A new mechanism of beverage-drug interaction. J. Pharm. Sci. 2014, 104, 266–275.
33. Feng, S.; Yuan, Z.; Yao, X.; Ma, W.; Liu, L.; Liu, Z.; Xie, Y. Tangeretin, a citrus pantamethoxyflavone, antagonizes ABCB1-mediated multidrug resistance by inhibiting its transport function. Pharmacol. Res. 2016, 110, 193–204.
34. Bedada, S.K.; Neerati, P. Resveratrol pretreatment affects CYP2E1 activity of chlorzoxazone in healthy human volunteers. Phytother. Res. 2016, 30, 463–468.
35. Bedada, S.K.; Yellu, N.R.; Neerati, P. Effect of resveratrol treatment on the pharmacokinetics of diclofenac in healthy human volunteers. Phytother. Res. 2016, 30, 397–401.
36. Merriam-Webster’s Medical Dictionary. Available online: https://www.merriam-webster.com/dictionary/herb (accessed on 23 August 2017).
37. Beneke, C.; Viljoen, A.; Hamman, J. Modulation of drug efflux by aloe materials: An in vitro investigation across rat intestinal tissue. Pharmacogn. Mag. 2013, 9, S44–S48.
38. Wallis, L.; Malan, M.; Gouws, C.; Steyn, D.; Ellis, S.; Abay, E.; Wiesner, L.; Otto, D.P.; Hamman, J. Evaluation of isolated fractions of Aloe vera gel materials on indinavir pharmacokinetics: In vitro and in vivo studies. Curr. Drug Deliv. 2016, 13, 471–480.
39. Akaberi, M.; Sobhani, Z.; Javadi, B.; Sahebkar, A.; Emami, S.A. Therapeutic effects of Aloe spp. in traditional and modern medicine: A review. Biomed. Pharmacother. 2016, 84, 759–772.
40. Sanchez-Machado, D.I.; López-Cervantes, J.; Sendón, R.; Sanches-Silva, A. Aloe vera: Ancient knowledge with new frontiers. Trends Food Sci. Technol. 2017, 61, 94–102.
41. Chen, W.; Lu, Z.; Viljoen, A.; Hamman, J. Intestinal drug transport enhancement by Aloe vera. Planta Med. 2009, 75, 587–595.
42. Beneke, C.; Viljoen, A.; Hamman, J. In vitro drug absorption enhancement effects of Aloe vera and Aloe ferox. Sci. Pharm. 2012, 80, 475–486.
43. Lebitsa, T.; Viljoen, A.; Lu, Z.; Hamman, J. In vitro drug permeation enhancement potential of aloe gel materials. Curr. Drug Deliv. 2012, 9, 297–304.
44. De Bruyn, S.; Willers, C.; Steyn, D.; Steenekamp, J.; Hamman, S. Development and evaluation of a double-phase multiple-unit dosage form for enhanced insulin intestinal delivery. Drug Deliv. Lett. 2018, 8, 52–60.
45. Vinson, J.A.; Al Kharrat, H.; Andreoli, L. Effect of Aloe vera preparations on the human bioavailability of vitamins C and E. Phytomedicine 2005, 12, 760–765.
46. Ojewole, E.; Mackraj, I.; Akhundov, K.; Hamman, J.; Viljoen, A.; Olivier, E.; Wesley-Smith, J.; Govender, T. Investigating the effect of Aloe vera gel on the buccal permeability of didanosine. Planta Med. 2012, 78, 354–361.
47. Fox, L.T.; Gerber, M.; du Preez, J.L.; du Plessis, J.; Hamman, J.H. Skin permeation enhancement effects of the gel and whole-leaf materials of Aloe vera, Aloe marlothii and Aloe ferox. J. Pharm. Pharmacol. 2014, 67, 96–106.
48. Chen, T.; Cao, H.; Zhu, S.; Lu, Y.; Shang, Y.; Wang, M.; Tang, Y.; Zhu, L. Investigation of the binding of Salvianolic acid B to human serum albumin and the effect of metal ions on the binding. Spectrochim. Acta Mol. Biomol. Spectrosc. 2011, 81, 645–652.
49. Peng, X.; Qi, W.; Huang, R.; Su, R.; He, Z. Elucidating the influence of gold nanoparticles on the binding of Salvianolic acid B and rosmarinic acid to bovine serum albumin. PLoS ONE 2015, 10, e0118274.
50. Shao, X.; Ai, N.; Xu, D.; Fan, X. Exploring the interaction between Salvia miltiorrhiza and human serum albumin: Insights from herb-drug interaction reports, computional analysis and experimental studies. Spectrochim. Acta Mol. Biomol. Spectrosc. 2016, 161, 1–7.
51. Chatterjee, U.R.; Ray, S.; Micard, V.; Ghosh, D.; Ghosh, K.; Bandyopadhyay, S.S.; Ray, B. Interaction with bovine serum albumin of anti-oxidative pectic arabinogalactan from Andrographis paniculata. Carbohydr. Polym. 2014, 101, 342–348.
52. Merriam-Webster’s Medical Dictionary. Available online: https://www.merriam-webster.com/dictionary/dietary%20supplement (accessed on 24 August 2017).
53. Teng, Y.; Sheu, M.; Hsieh, Y.; Wang, R.; Chiang, Y.; Hung, C. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function. Phytomedicine 2016, 23, 316–323.
54. Caterina, P.; Antonello, D.P.; Chiara, G.; Chiara, C.; Giacomo, L.; Antonio, S.; Giovambiattista, D.S.; Luca, G. Pharmacokinetic drug-drug interaction and their implication in clinical management. J. Res. Med. Sci. 2013, 18, 600–609.
55. Dalzell, A.M.; Mistry, P.; Wright, J.; Williams, F.M.; Brown, C.D.A. Characterization of multidrug transporter-mediated efflux of avermectins in human and mouse neuroblastoma cell lines. Toxicol. Lett. 2015, 235, 189–198.
56. Kigen, G.; Edwards, G. Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers. BMC Pharmacol. Toxicol. 2017, 18.
57. Marada, V.V.V.R.; Flörl, S.; Kühne, A.; Burckhardt, G.; Hagos, Y. Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur. J. Med. Chem. 2015, 92, 723–731.
58. Valdez, B.C.; Hassan, M.; Andersson, B.S. Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions. Exp. Hematol. 2017, 52, 65–71.
59. Fujita, Y.; Noguchi, K.; Suzuki, T.; Katayama, K.; Sugimoto, Y. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein. BMC Res. Notes 2013, 6, 445.
60. Weiss, J.; Becker, J.P.; Haefeli, W.E. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro. Int. J. Antimicrob. Agents 2014, 43, 184–188.